{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:12:06Z","timestamp":1789542726878,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T00:00:00Z","timestamp":1185753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p> <jats:italic>Introduction:<\/jats:italic> There is emerging evidence for clinical superiority of catheter ablation over rate and rhythm control strategies in paroxysmal atrial fibrillation (PAF). The objective of this study was to compare costs related to medical therapy versus catheter ablation for PAF in Ontario (Canada).<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> Costs related to medical therapy in the analysis included the cost of anticoagulation, rate and rhythm control medications, noninvasive testing, physician follow\u2010up visits, and hospital admissions, as well as the cost of complications related to this management strategy. Costs related to catheter ablation were assumed to include the cost of the ablation tools (electroanatomic mapping or intracardiac echocardiography\u2010guided pulmonary vein ablation), hospital and physician billings, and costs related to periprocedural medical care and complications. Costs related to these various elements were obtained from the Canadian Registry of Atrial Fibrillation (CARAF), government fee schedules, and published data. Sensitivity analyses looking at a range of initial success rates (50\u201375%) and late attrition rates (1\u20135%), prevalence of congestive heart failure (CHF) (20\u201360%), as well as discounting varying from 3% to 5% per year were performed.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> The cost of catheter ablation ranged from $16,278 to $21,294, with an annual cost of $1,597 to $2,132. The annual cost of medical therapy ranged from $4,176 to $5,060. Costs of ongoing medical therapy and catheter ablation for PAF equalized at 3.2\u20138.4 years of follow\u2010up.<\/jats:p><jats:p> <jats:italic>Conclusion:<\/jats:italic> Catheter ablation is a fiscally sensible alternative to medical therapy in PAF with cost equivalence after 4 years.<\/jats:p>","DOI":"10.1111\/j.1540-8167.2007.00902.x","type":"journal-article","created":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T21:13:46Z","timestamp":1185830026000},"page":"907-913","source":"Crossref","is-referenced-by-count":53,"title":["Cost Comparison of Catheter Ablation and Medical Therapy in Atrial Fibrillation"],"prefix":"10.1111","volume":"18","author":[{"given":"YAARIV","family":"KHAYKIN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CARLOS A.","family":"MORILLO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALLAN C.","family":"SKANES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AARON","family":"MCCRACKEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KARIN","family":"HUMPHRIES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHARLES R.","family":"KERR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,7,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00559-0"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.10.946"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.3.229"},{"key":"e_1_2_7_5_2","first-page":"533","article-title":"Preventing stroke in atrial fibrillation: Why are so many eligible patients not receiving anticoagulant therapy?","volume":"161","author":"Connolly SJ","year":"1999","journal-title":"CMAJ"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809033391003"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2007.00823.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.20.2463"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.16.1879"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.11.1203"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4601.098517"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2007.00981.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01972-1"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00577-1"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.08.037"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.122518"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000121736.16643.11"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021375"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200422100-00005"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.19.2365"},{"key":"e_1_2_7_22_2","unstructured":"Ontario Drug Benefit Formulary.2004. Cited; available from:http:\/\/www.health.gov.on.ca\/english\/providers\/program\/drugs\/odbf_eformulary.html"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2000.36001.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.10.973"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.09.056"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2004.02.007"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041018"},{"key":"e_1_2_7_28_2","unstructured":"Ontario Ministry of Health and Long\u2010term Care Physician Schedule of Benefits.2003."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2004.04428.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000157153.30978.67"},{"key":"e_1_2_7_31_2","unstructured":"NooraniHZ YeeR MarshallD ConnollyS NicholG O'BrienB:Radiofrequency catheter ablation for cardiac arrhythmias: A clinical and economic review in Canadian Coordinating Office for Health Technology Assessment.2002 Canadian Coordinating Office for Health Technology Assessment."},{"key":"e_1_2_7_32_2","unstructured":"Health Costing in Alberta.2003. Annual Report."},{"key":"e_1_2_7_33_2","unstructured":"Calgary Health Region Price Guide 2005\u201306."},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.21.2634"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050955"},{"key":"e_1_2_7_36_2","unstructured":"JaisP CauchemezB MacleL et al.:Atrial fibrillation ablation versus antiarrhythmic drugs: A multicenter randomized trial. in Heart Rhythm Society 2006 Scientific Sessions.2006. Boston MA ."},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.177292"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009795330454"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01302-X"},{"key":"e_1_2_7_41_2","unstructured":"Statistics Canada.Population by sex and age group.January 2006. Available at:http:\/\/www40.statcan.ca101\/cst01\/demo10a.htm"},{"key":"e_1_2_7_42_2","unstructured":"U.S. opportunities in the management of atrial fibrillation. Report #055\u20101\u2010US\u20101002 (October 2002) Health Research International. Available at:http:\/\/www.healthri.com"}],"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8167.2007.00902.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8167.2007.00902.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:38:14Z","timestamp":1697074694000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8167.2007.00902.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,30]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1540-8167.2007.00902.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8167.2007.00902.x","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,30]]}}}